LCLarvol Clinicinlarvol.hashnode.dev·Sep 27, 2024 · 2 min readEfficacy and Safety of Relugolix in Advanced Prostate Cancer: Subgroup Analysis of Concomitant Therapies from the HERO StudyBackground: In the phase 3 HERO study, the oral GnRH receptor antagonist, relugolix, demonstrated suppression of testosterone to castrate levels in 96.7% of patients, which was superior to leuprolide, and a 54% lower risk of major adverse cardiovascu...00
LCLarvol Clinicinlarvol.hashnode.dev·Sep 27, 2024 · 2 min readEnhancing PSA Screening Recommendations: The Impact of Color-Coding and Shared Decision-Making in a Diverse Patient PopulationMethods:We enrolled an age- (30–49, 50–69, 70–89 years) and sex-stratified sample of 18 patients (PTs) who underwent a physical examination at 2 urban hospitals by each of 12 primary care MDs. We assigned screening guideline formatting (color-coding ...00
LCLarvol Clinicinlarvol.hashnode.dev·Sep 27, 2024 · 2 min readOvercoming Platelet-Induced Resistance and Enhancing Anti-Invasive ActivityBackground:A phase I/II clinical trial in advanced hepatocellular carcinoma (HCC) conducted by Yakult Honsha (NCT02400788) indicated the combination of the HDAC inhibitor resminostat and sorafenib was beneficial compared to sorafenib for patients wit...00
LCLarvol Clinicinlarvol.hashnode.dev·Sep 27, 2024 · 2 min readStudy Overview: Combination of FTD/TPI with IRI in Advanced Gastric and Esophagogastric Junction Cancer (aGEC)Background:In 2L+ aGEC, taxanes +/- ramucirumab or IRI are recommended treatment options. IRI has been tested in multiple single arm and randomized trials in second line (2L)+ aGEC, with reported objective response rates (ORR) in the 15–29% range and...00
LCLarvol Clinicinlarvol.hashnode.dev·Sep 27, 2024 · 1 min readInclusion and Exclusion Criteria for Peripheral T Cell Lymphoma StudyAge range 14–70 years old; ECOG performance status 0–2; Estimated survival time > 3 months Histological confirmed Peripheral T cell lymphoma None of chemotherapy or radiotherapy has been previously used None of chemotherapy contraindication: hemoglob...00